Adelaide Research & Scholarship
Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/9303
| Citations | ||
| Scopus | Web of Science® | Altmetric |
|---|---|---|
|
?
|
?
|
|
| Type: | Journal article |
| Title: | Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis |
| Author: | Branford, S. Rudzki, Z. Walsh, S. Parkinson, I. Grigg, A. Szer, J. Taylor, K. Hermann, R. Seymour, J. Arthur, C. Joske, D. Lynch, K. Hughes, T. |
| Citation: | Blood, 2003; 102(1):276-283 |
| Publisher: | American Society of Hematology |
| Issue Date: | 2003 |
| ISSN: | 0006-4971 1528-0020 |
| Statement of Responsibility: | Susan Branford, Zbigniew Rudzki, Sonya Walsh, Ian Parkinson, Andrew Grigg, Jeff Szer, Kerry Taylor, Richard Herrmann, John F. Seymour, Chris Arthur, David Joske, Kevin Lynch, and Tim Hughes |
| Abstract: | Abstract not available |
| Keywords: | Humans Disease Progression Benzamides Piperazines Pyrimidines Fusion Proteins, bcr-abl Adenosine Triphosphate Prognosis Survival Analysis DNA Mutational Analysis Binding Sites Protein Structure, Tertiary Drug Resistance, Neoplasm Mutation Genes, abl Adult Aged Middle Aged Female Male Leukemia, Myelogenous, Chronic, BCR-ABL Positive Imatinib Mesylate |
| Rights: | © 2003 by The American Society of Hematology |
| DOI: | 10.1182/blood-2002-09-2896 |
| Published version: | http://dx.doi.org/10.1182/blood-2002-09-2896 |
| Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.